EXPERT OPINION
Topical anti-glaucoma medication will continue to be used in the management of this blinding disease for the foreseeable future.
Treatment outcomes will benefit from minimized exposure to benzalkonium chloride.
The development of alternative preservatives, preservative-free topical options, and non-drop therapeutics such as drug-eluting systems for the delivery of ocular medications, will be very helpful in the care of glaucoma patients.